导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.88% | 2663/4773 |
| 近一周 | -1.18% | 1775/5465 |
| 近一月 | -2.32% | 1582/5421 |
| 近一季 | -5.13% | 1974/5231 |
| 近半年 | -2.95% | 2334/4920 |
| 近一年 | 1.19% | 2547/4394 |
| 近两年 | 36.53% | 2051/2954 |
| 近三年 | 24.40% | 1326/2253 |
| 成立以来 | 246.04% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.63% 1891/4961 |
8.79% 2542/5312 |
- - |
- - |
| 2025 | 13.30% 2651/4813 |
0.38% 1876/3635 |
2.50% 1529/4076 |
7.99% 3424/4524 |
1.97% 1124/4813 |
| 2024 | 15.02% 975/3463 |
2.02% 829/2808 |
-1.21% 983/3014 |
15.62% 1671/3129 |
-1.30% 1651/3463 |
| 2023 | -1.58% 523/2656 |
5.40% 789/2280 |
-1.47% 493/2385 |
-1.10% 481/2515 |
-4.17% 900/2655 |
| 2022 | -12.04% 269/2207 |
-10.26% 385/1919 |
4.88% 965/2016 |
-10.05% 343/2113 |
3.90% 621/2208 |
| 2021 | -1.80% 819/1822 |
-1.86% 546/1255 |
2.53% 1001/1330 |
-7.65% 1071/1466 |
5.67% 275/1822 |
| 2020 | 33.32% 460/1250 |
-7.70% 563/1028 |
13.72% 599/1067 |
12.26% 398/1164 |
13.15% 388/1184 |
| 2019 | 39.59% 279/1092 |
24.49% 507/754 |
-0.43% 263/804 |
3.67% 241/850 |
8.63% 300/918 |
| 2018 | -22.81% 259/834 |
- - |
- - |
- - |
-12.89% 490/691 |
| 2017 | 49.52% 10/714 |
- - |
- - |
- - |
- - |
| 2016 | -2.73% 136/605 |
- - |
- - |
- - |
- - |
| 2015 | 17.57% 132/575 |
- - |
- - |
- - |
- - |
| 2014 | 26.05% 180/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 建信央视财经50指数(LOF) VS. 长安沪深300非周期A(740101) |